
STRO
Sutro Biopharma Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.95625
Open
0.930
VWAP
0.91
Vol
362.04K
Mkt Cap
74.93M
Low
0.8706
Amount
327.67K
EV/EBITDA(TTM)
--
Total Shares
81.79M
EV
-175.96M
EV/OCF(TTM)
--
P/S(TTM)
1.07
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
13.25M
-10.51%
--
--
13.51M
+58.57%
--
--
14.25M
-44.55%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Sutro Biopharma, Inc. (STRO) for FY2025, with the revenue forecasts being adjusted by 20.45% over the past three months. During the same period, the stock price has changed by -1.71%.
Revenue Estimates for FY2025
Revise Upward

+20.45%
In Past 3 Month
Stock Price
Go Down

-1.71%
In Past 3 Month
5 Analyst Rating

91.61% Upside
Wall Street analysts forecast STRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 1.70 USD with a low forecast of 0.80 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
1 Sell
Hold

91.61% Upside
Current: 0.887

Low
0.80
Averages
1.70
High
2.00

91.61% Upside
Current: 0.887

Low
0.80
Averages
1.70
High
2.00
Piper Sandler
Neutral -> Overweight
upgrade
$2
2025-06-17
Reason
Piper Sandler
Price Target
$2
2025-06-17
upgrade
Neutral -> Overweight
Reason
Piper Sandler last night upgraded Sutro Biopharma to Overweight from Neutral with an unchanged price target of $2. The company plans to file three new drug applications on next-generation antibody-drug conjugates over the next three years, the analyst tells investors in a research note. The firm says Sutro ended Q1 with cash of $249M to fund operations into 2027 and currently trades at a negative $181M enterprise value. Piper sees an attractive valuation at current share levels.
Piper Sandler
Neutral -> Overweight
upgrade
$2
2025-06-15
Reason
Piper Sandler
Price Target
$2
2025-06-15
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded Sutro Biopharma to Overweight from Neutral with an unchanged price target of $2.
BofA
Underperform
downgrade
$1
2025-05-19
Reason
BofA
Price Target
$1
2025-05-19
downgrade
Underperform
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
to
Hold
Downgrades
$12 → $2
2025-03-17
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$12 → $2
2025-03-17
Downgrades
Strong Buy
to
Hold
Reason
B of A Securities
Tazeen Ahmad
Strong Buy
to
Sell
Downgrades
$11 → $1
2025-03-14
Reason
B of A Securities
Tazeen Ahmad
Price Target
$11 → $1
2025-03-14
Downgrades
Strong Buy
to
Sell
Reason
Wedbush
David Nierengarten
Buy
to
Hold
Downgrades
$8 → $2
2025-03-14
Reason
Wedbush
David Nierengarten
Price Target
$8 → $2
2025-03-14
Downgrades
Buy
to
Hold
Reason
Wedbush downgraded Sutro Biopharma to Neutral from Outperform with a price target of $2, down from $8. The company announced a reprioritization of its portfolio, which includes the de-prioritization of luvelta, the analyst tells investors in a research note. While Wedbush believes Sutro's XpressCF platform is de-risked, in the absence of meaningful catalysts that can move shares in the near-term, it is moving to the sidelines.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sutro Biopharma Inc (STRO.O) is -0.64, compared to its 5-year average forward P/E of -3.31. For a more detailed relative valuation and DCF analysis to assess Sutro Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.31
Current PE
-0.64
Overvalued PE
-0.25
Undervalued PE
-6.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.71
Current EV/EBITDA
1.00
Overvalued EV/EBITDA
1.37
Undervalued EV/EBITDA
-2.80
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
9.25
Current PS
1.27
Overvalued PS
16.63
Undervalued PS
1.86
Financials
Annual
Quarterly
FY2025Q1
YoY :
+33.76%
17.40M
Total Revenue
FY2025Q1
YoY :
-16.12%
-47.47M
Operating Profit
FY2025Q1
YoY :
+30.50%
-75.97M
Net Income after Tax
FY2025Q1
YoY :
-4.21%
-0.91
EPS - Diluted
FY2025Q1
YoY :
+5.94%
-69.06M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+286.25%
-298.80
FCF Margin - %
FY2025Q1
YoY :
-2.44%
-436.62
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.3M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
6.3M
Volume
Months
6-9
3
4.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
STRO News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
08:14:52
Sutro Biopharma enters research collaboration with FDA for ADC standards

2025-06-02 (ET)
2025-06-02
08:08:40
Sutro Biopharma appoints Greg Chow as CFO

2025-03-16 (ET)
2025-03-16
18:37:24
Sutro Biopharma presents expanded data from REFRalphaME-01 trial

Sign Up For More Events
Sign Up For More Events
News
2.0
06-24NASDAQ.COMRGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
2.0
06-24NASDAQ.COMStrength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?
4.0
06-16BenzingaPiper Sandler Upgrades Sutro Biopharma to Overweight, Maintains Price Target to $2
Sign Up For More News
People Also Watch

VOXX
VOXX International Corp
7.490
USD
0.00%

FEIM
Frequency Electronics Inc
27.980
USD
+4.79%

VIRC
Virco Mfg Corp
8.250
USD
+2.87%

NKTR
Nektar Therapeutics
25.000
USD
+1.71%

SSTI
SoundThinking Inc
12.130
USD
-2.18%

BEEP
Mobile Infrastructure Corp
3.850
USD
+1.85%

SCPH
scPharmaceuticals Inc
5.600
USD
-4.11%

STRT
Strattec Security Corp
64.410
USD
-1.17%

PAYS
Paysign Inc
8.150
USD
-4.79%

PLX
Protalix Biotherapeutics Inc
1.510
USD
-2.58%
FAQ

What is Sutro Biopharma Inc (STRO) stock price today?
The current price of STRO is 0.8872 USD — it has decreased -3.06 % in the last trading day.

What is Sutro Biopharma Inc (STRO)'s business?

What is the price predicton of STRO Stock?

What is Sutro Biopharma Inc (STRO)'s revenue for the last quarter?

What is Sutro Biopharma Inc (STRO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Sutro Biopharma Inc (STRO)'s fundamentals?

How many employees does Sutro Biopharma Inc (STRO). have?
